Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry

Management of CML-blast crisis

(2016) Rüdiger Hehlmann et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia

(2016) Lan-Ping Xu et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT)

(2016) J R Passweg et al.   BONE MARROW TRANSPLANTATION

Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis

(2016) Yan-Ru Ma et al.   CLINICAL TRANSPLANTATION

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

(2016) Hannah Bower et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

(2016) V S Hoffmann et al.   LEUKEMIA

Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome

(2015) Agnieszka Piekarska et al.   ANNALS OF HEMATOLOGY

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

(2015) A Gratwohl et al.   LEUKEMIA

Allogeneic transplantation for CML in the TKI era: striking the right balance

(2015) Andrew J. Innes et al.   Nature Reviews Clinical Oncology

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

(2015) Koji Sasaki et al.   Lancet Haematology

Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis

(2014) H Jiang et al.   BONE MARROW TRANSPLANTATION

Clinical and biological predictors of outcome following relapse of CML post-allo-SCT

(2014) N A Jain et al.   BONE MARROW TRANSPLANTATION

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

(2013) M. Hoglund et al.   BLOOD

Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase

(2013) Maro Ohanian et al.   Clinical Lymphoma Myeloma & Leukemia

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

(2012) Anthony Oyekunle et al.   ANNALS OF HEMATOLOGY

First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia

(2012) D Rea et al.   LEUKEMIA

EBMT Risk Score Predicts Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Who Have Failed a Previous Transplantation Procedure

(2011) Katayoun Rezvani et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase

(2011) Q. Jiang et al.   BLOOD

Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis

(2011) H J Khoury et al.   BONE MARROW TRANSPLANTATION

Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China

(2010) Qi-fa Liu et al.   ANNALS OF HEMATOLOGY

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV

(2009) S. Saussele et al.   BLOOD

Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT

(2009) Y Chalandon et al.   BONE MARROW TRANSPLANTATION

Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib

(2009) Massimo Breccia et al.   LEUKEMIA RESEARCH

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

(2008) S. J. Lee et al.   BLOOD